Candriam S.C.A. Kymera Therapeutics, Inc. Transaction History

Candriam S.C.A.

$16.3 Billion
Q2 2024

A detailed history of Candriam S.C.A. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 238,165 shares of KYMR stock, worth $11.6 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

238,165

Previous 328,302 27.46%

Holding current value

$11.6 Million

Previous $13.2 Million 46.13%

% of portfolio

0.04%

Previous 0.09%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	SELL	$29.85 - $39.42 $2.69 Million - $3.55 Million	-90,137 Reduced 27.46%	238,165 $7.11 Million
Q1 2024 May 03, 2024	SELL	$22.9 - $43.57 $343,500 - $653,550	-15,000 Reduced 4.37%	328,302 $13.2 Million
Q4 2023 Feb 14, 2024	SELL	$10.97 - $26.84 $1.59 Million - $3.89 Million	-145,004 Reduced 29.7%	343,302 $8.74 Million
Q2 2023 Aug 08, 2023	SELL	$22.4 - $34.92 $519,007 - $809,096	-23,170 Reduced 4.53%	488,306 $11.2 Million
Q4 2022 Feb 13, 2023	SELL	$19.57 - $30.92 $746,438 - $1.18 Million	-38,142 Reduced 6.94%	511,476 $12.8 Million
Q3 2022 Nov 10, 2022	BUY	$20.91 - $34.27 $1.67 Million - $2.73 Million	79,758 Added 16.97%	549,618 $12 Million
Q2 2022 Aug 03, 2022	BUY	$14.13 - $42.55 $779,227 - $2.35 Million	55,147 Added 13.3%	469,860 $9.25 Million
Q1 2022 May 13, 2022	BUY	$35.3 - $64.68 $419,858 - $769,303	11,894 Added 2.95%	414,713 $17.6 Million
Q4 2021 Feb 10, 2022	BUY	$49.91 - $65.56 $390,695 - $513,203	7,828 Added 1.98%	402,819 $25.6 Million
Q3 2021 Nov 09, 2021	SELL	$47.8 - $66.66 $764,800 - $1.07 Million	-16,000 Reduced 3.89%	394,991 $23.2 Million
Q2 2021 Jul 20, 2021	BUY	$31.08 - $51.95 $12.8 Million - $21.4 Million	410,984 Added 5871200.0%	410,991 $19.9 Million
Q1 2021 Apr 29, 2021	BUY	$35.64 - $85.46 $249 - $598	7 New	7 $0

Others Institutions Holding KYMR

# of Institutions

160

Shares Held

63.1M

Call Options Held

22.6K

Put Options Held

14.4K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.66B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account